| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/17/2005 | US20050037382 Methods and compositions for treating and preventing autoimmune disorders |
| 02/17/2005 | US20050037376 Sulfatase polypeptide for use in treatment and prevention of microbial infection, cell proliferative, neurodegenerative and cardiovascular disorders |
| 02/17/2005 | US20050037372 Expression vector comprising nucleotide sequences coding immunglobulin which binds nuclear matrix protein for use in generating diagnosing, classifiyiing and prognosing hepatic cell proliferative disorders |
| 02/17/2005 | US20050037339 Methods of selecting internalizing antibodies |
| 02/17/2005 | US20050037092 Vascularization therapy by highly concentrated carbonated warm water bath |
| 02/17/2005 | US20050037089 Administering a bone remodeling agent such as parathyroid hormone and a dietary supplement comprising calcium and phosphorus |
| 02/17/2005 | US20050037088 Process of making flowable hemostatic compositions and devices containing such compositions |
| 02/17/2005 | US20050037084 Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability |
| 02/17/2005 | US20050037081 Novel formulation |
| 02/17/2005 | US20050037069 Solid and stable creatine/citric acid composition(s) and compositions carbohydrate(s) or hydrates thereof, method for the production and use thereof |
| 02/17/2005 | US20050037049 use of benzyl ester of hyaluronic acid and/or derivatives, in association with other biopolymers and antitumor agents to fill cavities when the tumor have been surgically removed |
| 02/17/2005 | US20050037032 Composition and method of treatment for urogenital conditions |
| 02/17/2005 | US20050037026 such as Alzheimer's disease; amyloid precursor proteins; comprises diphtheria toxoid as carrier |
| 02/17/2005 | US20050037018 Vaccination with a synergistic combination of a Hepatitis C Virus E1 vaccine and an antiviral agent, such as an interferon; improved immunostimulation |
| 02/17/2005 | US20050037014 T helper cell epitopes |
| 02/17/2005 | US20050037013 Prevention and treatment of synucleinopathic and amyloidogenic disease |
| 02/17/2005 | US20050037012 A polypeptide covalently attached with a polyethylene glycol propionaldehyde group having anti-hepatitis C activity |
| 02/17/2005 | US20050037009 Methods and reagents for protease inhibition |
| 02/17/2005 | US20050037008 unexpected discovery that the inhibition or antagonism of TNF decreases the expression of Vascular Endothelial Growth Factor (VEGF) or Vascular Permeability Factor (VPF). VEGF has been implicated in the angiogenesis in cancer, vascular diseases and rheumatoid arthritis |
| 02/17/2005 | US20050037007 In a tissue, organ or wound site using a synergistic mixture of transforming growth factor beta inhibitors and agents that degrade the excess accumulated extracellular matrix; fibrotic diseases and scarring |
| 02/17/2005 | US20050037006 Antithrombotic agents |
| 02/17/2005 | US20050037005 5c8 Antigen |
| 02/17/2005 | US20050037003 Administering a soluble lymphotoxin- beta receptor, an antibody directed against LT- beta receptor, or an antibody directed against surface LT ligand with a carrier; multiple sclerosis, vision defects, psoriasis, inflammatory bowel disease; antidiabetic agents |
| 02/17/2005 | US20050036994 Compounds and methods for downregulating the effects of TGF-beta |
| 02/17/2005 | US20050036991 For preventing and/or treating transplant/xenotransplant rejection; interleukin-1B converting enzyme inhibitors |
| 02/17/2005 | US20050036988 Administering vector which transduces hepatic stellate cells which suppresses collagen and/or tumor growth factor-beta expression; kits |
| 02/17/2005 | US20050036986 Antisense agents; gene expression inhibition; prostate cancer; hyperplasia; carcinoma |
| 02/17/2005 | US20050036985 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 02/17/2005 | US20050036984 Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof |
| 02/17/2005 | US20050036981 Pyridoxal 5' phosphate (PLP) dependent enzymes, recombinant methioninase (rMETase), extend serum half-life, extend in vivo period of methionine depletion in host, and decrease immunogenicity; cancer |
| 02/17/2005 | US20050036976 Topical skin care composition |
| 02/17/2005 | US20050036966 Medicine for preventing and treating bromidrosis |
| 02/17/2005 | US20050036951 Methods of treating lung diseases |
| 02/17/2005 | US20050036950 spray-on topical wound debrider; nondripping; a fatty alcohol phosphate ester emulsifier composition that carries and uniformly distributes the proteolytic enzyme |
| 02/17/2005 | US20050036949 A pharmaceutical dispenser; a liquid formulation comprising nitric oxide; respiratory system diseases; atomizing |
| 02/17/2005 | DE10333509A1 New recognition molecules for the vascular endothelial growth factor gene, useful for treatment, diagnosis and monitoring of solid tumors and leukemia |
| 02/17/2005 | DE10333317A1 Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) Formulation for protein drugs without the addition of human serum albumin (HSA) |
| 02/17/2005 | DE10332685A1 Use of a modulator of specific potassium channels, expressed preferentially in the atrium, for treatment and prevention of arrhythmia, coronary disease and hypertension |
| 02/17/2005 | DE10331980A1 Verwendung von Calpain zur Identifizierung von schmerzmodulierenden Verbindungen Use of calpain to identify pain-compounds |
| 02/17/2005 | CA2678736A1 Novel multifunctional il-2 - il-18 fusion proteins |
| 02/17/2005 | CA2537555A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 02/17/2005 | CA2535448A1 Use of indomethacin and derivatives as broad-spectrum antiviral drugs and corresponding pharmaceutical compositions |
| 02/17/2005 | CA2535446A1 Methods for preventing neurological events |
| 02/17/2005 | CA2535098A1 Method for inhibiting bacterial colonisation |
| 02/17/2005 | CA2535029A1 Pharmaceutical compositions and methods for accelerating wound healing |
| 02/17/2005 | CA2534909A1 P16 mediated regulation of nmda receptors |
| 02/17/2005 | CA2534899A1 Polypeptides having brain-localizing activity and uses thereof |
| 02/17/2005 | CA2534708A1 Targeted carrier fusions for delivery of chemotherapeutic agents |
| 02/17/2005 | CA2534412A1 Conjugates of a polymer and a protein linked by an oxime linking group |
| 02/17/2005 | CA2534355A1 Compounds comprising lpa |
| 02/17/2005 | CA2533124A1 Use of cxcl6 chemokine in the prevention or repair of cartilage defects |
| 02/17/2005 | CA2532821A1 Use of human growth hormone in multiple system atrophy |
| 02/17/2005 | CA2532759A1 Active or passive immunization against proapoptotic neurotrophins for the treatment and/or prevention of neurodegenerative diseases |
| 02/17/2005 | CA2532721A1 Ra antigenic peptides |
| 02/17/2005 | CA2531773A1 Novel multifunctional cytokines |
| 02/17/2005 | CA2531228A1 Novel therapeutic fusion proteins |
| 02/17/2005 | CA2530482A1 Self-assembling peptides incorporating modifications and methods of use thereof |
| 02/17/2005 | CA2529196A1 Benzodiazepine cgrp receptor antagonists |
| 02/17/2005 | CA2528569A1 Method for producing a polypeptide |
| 02/17/2005 | CA2528510A1 Conserved hbv and hcv sequences useful for gene silencing |
| 02/17/2005 | CA2526274A1 Prostate stem cell antigen (psca) variants and subsequences thereof |
| 02/16/2005 | EP1507007A1 Cell cycle related proteins |
| 02/16/2005 | EP1507006A1 Method of screening remedy for renal failure |
| 02/16/2005 | EP1507005A2 Antisense modulation of BCL-X expression |
| 02/16/2005 | EP1507004A1 Method to inhibit the propagation of an undesired cell population |
| 02/16/2005 | EP1507002A2 Thermostable Taq polymerase fragment |
| 02/16/2005 | EP1506972A1 Insulin-like growth factor (IGF) I mutant variants |
| 02/16/2005 | EP1506971A1 Prokineticin polypeptides, related compositions and methods |
| 02/16/2005 | EP1506970A1 Compounds which can block the response to chemical substances or thermal stimuli or mediators of inflammation of nociceptors, production method thereof and compositions containing same |
| 02/16/2005 | EP1506969A1 Compounds with growth hormone releasing properties |
| 02/16/2005 | EP1506787A1 Vascular endothelial cell growth factor antagonists |
| 02/16/2005 | EP1506786A1 Medicinal compositions containing ghrelin |
| 02/16/2005 | EP1506785A1 Composition for treating or preventing hyperuricemia |
| 02/16/2005 | EP1506784A1 Identification of novel factors that block programmed cell death or apoptosis by targeting JNK |
| 02/16/2005 | EP1506776A1 Use of enzyme inhibitors of the dipeptidylpeptidase IV and/or of the aminopeptidase n , and pharmaceutical preparations thereof for the prevention or therapy of neurodegenerative diseases |
| 02/16/2005 | EP1506412A1 Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 2 (vpac2) |
| 02/16/2005 | EP1506409A1 Assays for modulators of asparaginyl hydroxylase |
| 02/16/2005 | EP1506404A2 Simultaneous detection of two analytes produced by a cell under the influence of a putative agent using a pin coated assay system |
| 02/16/2005 | EP1506400A2 Pathway of rantes-mediated chemokine synthesis in astrocytes and methods of use therefor |
| 02/16/2005 | EP1506398A2 Human secreted proteins |
| 02/16/2005 | EP1506317A2 Marker molecules associated with lung tumors |
| 02/16/2005 | EP1506306A2 Nucleic acids encoding a g-protein coupled receptor involved in islet cell signaling |
| 02/16/2005 | EP1506303A2 Enzymes |
| 02/16/2005 | EP1506295A2 Muteins of placental growth factor type 1, preparation method and application thereof |
| 02/16/2005 | EP1506285A2 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 02/16/2005 | EP1506234A1 Improved synthetic lipid mixtures for the preparation of a reconstituted surfactant |
| 02/16/2005 | EP1506233A1 Active complex of alpha-lactalbumin (hamlet) and cofactor |
| 02/16/2005 | EP1506232A1 Sodium channel regulators and modulators |
| 02/16/2005 | EP1506231A2 Hybrid and fusion polypeptide subunits of k+ channels |
| 02/16/2005 | EP1506230A1 Soluble formulations comprising monomeric insulin and acylated insulin |
| 02/16/2005 | EP1506229A1 Obg3 fragments inhibiting the conversion of active obg3 into less active obg3 and other compositions for treatment of metabolic disorders |
| 02/16/2005 | EP1506225A2 Novel peptide compositions and the use thereof, in particular, in the preparation of active pharmaceutical compositions against the hepatitis c virus |
| 02/16/2005 | EP1506220A1 Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
| 02/16/2005 | EP1506218A2 Reversible modification of membrane interaction |
| 02/16/2005 | EP1506215A2 Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same |
| 02/16/2005 | EP1506172A2 Hepatitis c virus inhibitors |
| 02/16/2005 | EP1506032A1 Aerosol drug inhibition of lung metastases |
| 02/16/2005 | EP1506020A2 Processes for inhibiting gene expression using polynucleotides |
| 02/16/2005 | EP1506015A2 Pharmaceutical combination of pde5 inhibitors with ace inhibitors |
| 02/16/2005 | EP1506013A1 Chimeric allograft tolerance induction, monitoring and maintenance |